The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Dequalinium (Fluomizin®) has been accepted for restricted use in the treatment of bacterial vaginosis where the initial treatment is ineffective or not well tolerated.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Drug Safety Update - November 2016||British Asthma Guideline Update »|